ClearPoint Neuro, Inc. Q4 FY2025 earnings call

Joe Burnett stated the company remains committed to developing a neuroecosystem for minimally invasive treatments. The company ended 2025 strongly with a strong financial quarter, a newly acquired and commercialized neurocritical care product line. Over the past five years, over $100 million was invested. The company has four growing product categories, a vetted pipeline, expanded manufacturing, a quality system, global regulatory approvals, an IT portfolio, over 150 global centers, and a strong cash position. The growth strategy has two phases: Fast Forward to penetrate a $1 billion market with four product segments and Essential Everywhere to build a new market for cell and gene therapy delivery. Danilo D'Alessandro walked through financial data, noting revenue components, margins, and expenses.

ClearPoint Neuro total revenues were $37 million for the year ended December 31, 2025, compared to $31.4 million in 2024. Revenue is made up of three components: biologics and drug delivery, neurosurgery navigation and therapy, and capital equipment and software. Biologics and drug delivery revenue increased 10% to $19 million in 2025. Neurosurgery navigation revenue grew to $14.8 million in 2025. Capital equipment and software revenue was $3.1 million in 2025. Fourth quarter 2025 total revenue was $10.4 million, with biologics and drug delivery revenue up 23% to $5.2 million, neurosurgery navigation and therapy revenue at $4.7 million, and capital equipment product and relief service revenue at $0.5 million.

For 2026, revenues are expected to be in the range of 52 to 56 million, taking into account FDA communications on rare diseases and integration efforts of recent acquisition. Expect all four product segments to grow double digits in 2026 through various means. The guidance is based on current FDA information on rare diseases and integration of Iris, with potential to revisit if positive news occurs.

Comments made on the call may include forward-looking statements which could differ materially. Actual results or trends could differ from forward-looking statements. For more information about risks and uncertainties, refer to the company's filings with the SEC.

Q: Follow-up related to 2026 guidance, including FDA communications on rare diseases and Iris integration, and organic growth.

A: On rare diseases, revenue from certain commercial launches is taken out; on Iris, European strategy reset. Expected balanced organic and inorganic growth in double digits.

Q: About core billion-dollar market and pathway to $200 million.

A: Expected 15%-20% growth, with potential large bumps from GLP capability and clinical evidence.

Q: On diversified offering and partners in expedited review.

A: Partners in expedited review for various indications, don't comment on timing of partner programs.

Q: On PRISM's expansion to neuro-oncology.

A: PRISM's first tumor clinical data to be published this year, expanding beyond functional neurosurgery.